Fortis Healthcare Limited has announced that its composite scheme of merger by absorption involving five wholly-owned subsidiaries has become effective from March 1, 2026. The healthcare company informed the stock exchanges through a regulatory filing on March 2, 2026, confirming the completion of the merger process.

Merger Implementation Details

The company filed the certified copy of the Hon'ble National Company Law Tribunal (NCLT) order with the Registrar of Companies on March 1, 2026 at 3:00 P.M. (IST). The filing was completed by submitting Form INC-28, in accordance with the applicable provisions of the Companies Act, 2013.

Subsidiaries Involved in Merger

The composite scheme of arrangement involves the merger by absorption of five wholly-owned subsidiaries with their respective shareholders and creditors:

• Fortis Emergency Services Limited (FESL)
• Fortis Cancer Care Limited (FCC)
• Fortis Health Management (East) Limited (FHML)
• Birdie & Birdie Realtors Private Limited (B&B)
• Fortis Hospitals Limited (FHSL)

Regulatory Compliance

The announcement was made pursuant to Regulations 30 and 51 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This follows the company's earlier intimation dated January 16, 2026, regarding the merger proceedings.

The filing was signed by Satyendra Chauhan, Company Secretary & Compliance Officer, confirming the completion of all regulatory requirements for the merger scheme to take effect.

Fortis Healthcare Limited has completed the mandatory newspaper publication of its Q3 FY26 unaudited financial results under SEBI regulations, following the company's strong financial performance for the quarter ended December 31, 2025. The healthcare giant reported consolidated revenues of INR 2,265 Cr, marking a significant 17.5% increase compared to Q3 FY25. Subsequently, the company held its earnings conference call on February 16, 2026, providing detailed insights into operational performance and future expansion plans.

Regulatory Compliance and Publication Details

Pursuant to Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published its financial results on February 14, 2026, in English daily "Financial Express" (all editions) and Punjabi daily "Rozana Spokesman" (Mohali edition). The publication ensures transparency and accessibility of financial information to all stakeholders. Additionally, the company released the transcript of its investors/analysts meet held on February 16, 2026, under Regulation 30.

Strong Financial Performance Highlights

The consolidated financial results showcase robust operational efficiency across both hospital and diagnostics businesses, with significant margin expansion and revenue growth. During the earnings call, MD and CEO Dr. Ashutosh Raghuvanshi highlighted the sustained growth momentum despite seasonal impacts from festivals in key geographies.

For the nine-month period ended December 31, 2025, consolidated revenues reached INR 6,763 Cr, demonstrating consistent growth momentum with a 17.1% increase. The company's net debt stands at INR 2,547 Cr with a net debt to EBITDA ratio of 1.24x as of December 31, 2025.

Hospital Business Drives Growth

The hospital business segment emerged as the primary growth driver, with revenues increasing substantially and margins improving across key specialties. Management noted that 13 facilities reported operating EBITDA above 20% during the nine-month period, contributing 77% of hospital revenues.

Strategic Acquisitions and Expansion Plans

During the earnings call, management announced the acquisition of 125-bedded People Tree Hospital in Yeshwanthpur, Bengaluru for INR 430 Cr in January 2026. The acquisition includes underlying land and an adjacent land parcel enabling future expansion to over 300 beds. The company also launched Adayu, a 36-bedded specialized mental health care facility in Gurugram in November 2025.

Diagnostics Business Performance

Agilus Diagnostics reported gross revenues of INR 371 Cr, reflecting 8.3% year-on-year growth. Operating EBITDA margin improved significantly to 23.1% from 14.4% in Q3 FY25. The business conducted 9.9 million tests during the quarter with a balanced B2C-B2B mix of 52-48.

Management Outlook and Future Strategy

CFO Vivek Goyal indicated expectations of continued growth trajectory with 4-5% ARPOB increases going forward. The company expects potential equity infusion from parent IHH Healthcare post the cooling period ending in May 2026. Management expressed confidence in maintaining growth momentum through brownfield expansions, strategic acquisitions, and operational improvements across existing facilities.